MARKET

FLXN

FLXN

Flexion
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.21
-0.54
-6.17%
Closed 16:56 03/27 EDT
OPEN
8.38
PREV CLOSE
8.75
HIGH
8.66
LOW
8.03
VOLUME
821.72K
TURNOVER
--
52 WEEK HIGH
22.98
52 WEEK LOW
5.01
MARKET CAP
316.51M
P/E (TTM)
-2.0874
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FLXN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FLXN stock price target is 27.44 with a high estimate of 36.00 and a low estimate of 20.00.

EPS

FLXN News

More
  • Flexion Therapeutics: Reporting Record Revenue On A Record Day For The Market
  • Seeking Alpha - Article · 03/19 15:00
  • Upside For Flexion Therapeutics Depends On How Well It Can Commercialize ZILRETTA In 2020
  • Seeking Alpha - Article · 03/18 13:21
  • Edited Transcript of FLXN earnings conference call or presentation 12-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 03/16 15:27
  • Flexion Therapeutics, Inc. Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
  • Simply Wall St. · 03/14 13:55

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About FLXN

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
More

Webull offers kinds of Flexion Therapeutics Inc stock information, including NASDAQ:FLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FLXN stock news, and many more online research tools to help you make informed decisions.